Avastin not as beneficial to older lung cancer patients | Dana-Farber Cancer Institute
1,947 views · Published 17 April 2012 · 1:28 · Indexed 31 October 2026
Channel: Dana-Farber Cancer Institute · 2012 · Education
Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, comments on a study that found adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare. Based on these results, the authors recommend that bevacizumab should not automatically be administered together with carboplatin-paclitaxel for older patients with non-small cell lung cancer. Rather, clinicians should exercise caution in making treatment recommendations and use bevacizumab judiciously for their patients.
More from this channel
-
0:18
Importance of Joining the Stem Cell Registry | Dana-Farber Cancer Institute
-
0:20
How to Join the Stem Cell Registry | Dana-Farber Cancer Institute
-
0:18
How to Register as a Stem Cell Donor | Dana-Farber Cancer Institute
-
3:03
Sportscaster Jim Britt for the Jimmy Fund | Dana-Farber Cancer Institute
-
0:07
Dana-Farber Banners | Dana-Farber Cancer Institute
-
2:08
Barbers for the Jimmy Fund | Dana-Farber Cancer Institute
-
1:43
Pets | Dana-Farber Cancer Institute
-
1:34
Healthy Eating for the Holiday Season | Dana-Farber Cancer Institute